{"keywords": [{"value": "Valeant Pharmaceuticals International Inc", "rank": "1", "is_major": "N", "name": "organizations"}, {"value": "Drugs (Pharmaceuticals)", "rank": "2", "is_major": "N", "name": "subject"}], "headline": {"content_kicker": "Breakingviews", "main": "Video: Valeant Effort"}, "byline": {"organization": "REUTERS", "original": "By REUTERS", "person": []}, "web_url": "http://www.nytimes.com/2015/10/27/business/dealbook/video-valeant-effort.html", "source": "The New York Times", "subsection_name": "DealBook", "slideshow_credits": null, "type_of_material": "News", "_id": "562e664338f0d82f94187bfe", "multimedia": [], "pub_date": "2015-10-27T00:00:00Z", "print_page": null, "section_name": "Business Day", "word_count": "27", "blog": [], "news_desk": "Business", "snippet": "The embattled $40 billion pharmaceuticals company tried \u2013 but failed \u2013 to quell concerns about its convoluted dealings with distributors.", "document_type": "article", "abstract": null, "lead_paragraph": "The embattled $40 billion pharmaceuticals company tried \u2013 but failed \u2013 to quell concerns about its convoluted dealings with distributors."}